Peak night to watch the Lyrid Meteor Shower
'The Lyrids are sort of centered in the constellation of Lyra,' said ASU Planetarium Director Kenneth Carrell. 'Lyra is actually pretty easy to find because the Star Vega is in the constellation of Lyra.'
The star Vega is the brightest in the summertime night sky, and can be seen now around 11 p.m.
'You can look over in the east sometime around midnight or so, you should see a fairly bright star start to rise in the constellation of Lyra,' Carrell said.
The meteors are from a comet that passes by the Earth about every 400 years.
Carrell says that the ASU planetarium will be showing two new shows on campus.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
8 hours ago
- Business Wire
Venova Technologies Awarded $2.23M SBIR Phase II Grant From NIH For Novel Contraceptive Device
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Venova Technologies, Inc., a women-led startup developing a novel long-acting, hormone-free and copper-free female birth control device, has been awarded a $2.23M Small Business Innovation Research (SBIR) Phase II Grant from the National Institutes of Health (NIH). The SBIR program is a highly competitive, awards-based program designed to stimulate technological innovations developed by U.S. small businesses on a path to commercialization. This Phase II award accelerates the preclinical development of Venova's innovative cervical barrier device toward first-in-human clinical studies and brings the company's total funding to over $5M. According to a UCLA survey, 73% of women want a birth control method that is very effective and has limited side effects, but this does not currently exist. A 2023 study found that half of women will stop or switch their birth control method because of unwanted or adverse side effects. 'This award is a pivotal milestone that brings us one step closer to offering a new birth control option for women that is designed to be side-effect-free and addresses concerns of pain from IUD insertion,' said Emily Man, Co-Founder & CEO of Venova. 'Validation from the scientific community highlights the growing momentum and critical need for innovation in women's health.' 'It's more important than ever to provide a wide range of choices for contraception that can meet the needs of more patients,' said Dr. Katharine White, Chair of Obstetrics and Gynecology at Boston University Chobanian & Avedisian School of Medicine and Chief of Obstetrics and Gynecology for the Boston Medical Center Health System. Dr. White is also the Chief Medical Advisor at Venova. 'Offering more affordable options that address a variety of preferences will enable more women to achieve the family size that they truly desire.' About Venova Technologies Venova Technologies, Inc., is a women-led startup dedicated to empowering women to take full control over their reproductive health. The company is developing a novel long-acting female contraceptive barrier device. Headquartered in Cambridge, Mass., at The Engine built by MIT, Venova participates in this premier ecosystem for high-potential, Tough Tech startups. For more information, visit Follow Venova on LinkedIn at
Yahoo
9 hours ago
- Yahoo
Castle Biosciences' Founder, President and CEO Derek Maetzold Named a Most Admired CEO by the Houston Business Journal
The Houston Business Journal's Most Admired CEO Awards recognize chief executive officers who exemplify exceptional leadership, vision and values while guiding Houston's most successful and impactful organizationsFRIENDSWOOD, Texas, July 25, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its founder, president and chief executive officer Derek Maetzold has been named a 2025 Most Admired CEO by the Houston Business Journal. This prestigious honor celebrates leaders who have demonstrated outstanding financial stewardship, fostered inclusive and thriving workplace cultures, and made meaningful contributions to the greater Houston community. 'Derek's visionary leadership and unwavering values have shaped Castle Biosciences into what it is today: a company focused on improving patient outcomes through innovative diagnostic tests for skin cancers, Barrett's esophagus and uveal melanoma,' said Frank Stokes, chief financial officer of Castle Biosciences. 'Over nearly two decades, his leadership approach has exemplified how great vision and values can drive meaningful progress – building a company culture where patient needs remain at the center of strategic decisions and where personalized disease insights can translate into better care for those who need it most.' 'I am truly honored to receive this recognition from the Houston Business Journal,' said Maetzold. "This award validates our core belief that lasting impact comes from doing right by our team and never losing sight of the patients who depend on our work.' The award recipients will be honored at a special event held by the Houston Business Journal in August. About Castle BiosciencesCastle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors. Castle's current portfolio consists of tests for skin cancers, Barrett's esophagus and uveal melanoma. Additionally, the Company has active research and development programs for tests in these and other diseases with high clinical need, including its test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis seeking biologic treatment. To learn more, please visit and connect with us on LinkedIn, Facebook, X and Instagram. DecisionDx-Melanoma, DecisionDx-CMSeq, i31-SLNB, i31-ROR, DecisionDx-SCC, MyPath Melanoma, TissueCypher, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc. Investor Contact:Camilla Zuckeroczuckero@ Media Contact:Allison Marshallamarshall@ Source: Castle Biosciences Inc. Photos accompanying this announcement are available at: in to access your portfolio
Business Wire
a day ago
- Business Wire
Janux Therapeutics Highlights Pipeline Progress and Best-in-Class Potential of Novel Bispecific Platform for Autoimmune Diseases at Virtual R&D Day
SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technologies to its Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms, will host its virtual R&D Day today at 1:30 PM PT. The event will highlight the company's continued momentum in advancing its novel immunotherapy platforms—TRACTr and TRACIr, as well as ARM—designed to address significant unmet needs in oncology and autoimmune diseases. 'At Janux, we are guided by a deep commitment to scientific excellence and a belief that innovation should translate into meaningful outcomes for patients,' said David Campbell, Ph.D., President and CEO of Janux Therapeutics. 'The progress we've shared today across our TRACTr, TRACIr, and ARM platforms reflects our disciplined strategy to focus first on maximizing the benefit and value of our clinical program JANX007, second to harness the value of our clinical experience by bringing forward TRACTrs where we can potentially be first- and/or best-in-class, and third to utilize our T cell engager development expertise to enable platform technologies that address other clear gaps in the treatment landscape.' Creating an Opportunity to Further Differentiate JANX007 with TRACIr Combination Janux is advancing its CD28-based TRACIr platform designed to enhance T cell activation and durability of its CD3-based TRACTr platform. TRACIr was built on the same technology with the same tumor-activation and PK design features as TRACTr and combines tumor targeting with immune costimulation. The TRACIr platform represents a strategic extension of Janux's tumor-activated approach, designed to complement and enhance the clinical potential of its TRACTr portfolio, beginning with PSMA-TRACTr JANX007. While JANX007 has already demonstrated differentiated clinical activity in late-stage metastatic castration-resistant prostate cancer (mCRPC) patients, the addition of a PSMAxCD28-TRACIr introduces a costimulatory signal that may further enhance durability of response within the tumor microenvironment. This combination has the potential to drive more prolonged anti-tumor effects without increasing systemic toxicity, positioning Janux to further differentiate JANX007 in the mCRPC treatment landscape. IND-enabling studies are underway for the PSMA-TRACIr, with clinical trials in combination with JANX007 expected to begin in the second half of 2026. Expanding the TRACTr Platform into High-Value Oncology Indications Building upon learnings from the JANX007 and JANX008 clinical programs, Janux introduced its latest trophoblast cell surface antigen 2 (TROP2) TRACTr program. This next-generation TROP2-TRACTr was engineered for potential best-in-class safety and efficacy across a broad range of TROP2-expressing tumors, including breast, lung and bladder cancers. Janux's TROP2-TRACTr exemplifies the TRACTr technology's ability to create high-value T cell engager (TCE) product candidates directed at tumor targets that contemporary TCE technologies have been unable to access due to broad healthy tissue expression. Janux's TROP2-TRACTr product candidate demonstrated strong potency across multiple tumor types, activity at low TROP2 expression levels, and was well tolerated in non-human primates with no signs of cytokine release syndrome (CRS) or healthy tissue toxicity. This preclinical data also displayed the ability to overcome limitations of existing TROP2-targeted therapies, including antibody drug conjugates. These findings support a wide therapeutic window and the potential for best-in-class performance in TROP2-expressing solid tumors. IND-enabling activities are planned in the second half of 2025. ARM Platform Redefines T-Cell Engagers for Autoimmune Disease and Oncology Janux also introduced its Adaptive Immune Response Modulator (ARM) bispecific platform, designed to overcome the limitations of conventional TCEs in autoimmune diseases and oncology. Builds upon Janux's expertise to redesign bispecific TCEs. Differentiated non-clinical profile provides best-in-class opportunity in autoimmune diseases. Potential broad applicability across multiple disease areas. Large safety window and off-the-shelf format position it for higher dosing, rapid development and potential best-in-class performance. The lead program, a CD19-ARM, has displayed rapid, deep and durable B-cell depletion in periphery and tissues with a prolonged memory B cell reset while maintaining a large safety window in non-human primates, supporting a potential best-in-class profile. ARMs exhibit differentiated durable T cell activity with reduced T cell exhaustion preclinically. The program demonstrated prolonged memory B-cell depletion and immune reset from a single subcutaneous dose, reflecting the durability seen with CD19 CAR-T therapies but with greater safety and convenience. ARMs displayed potential to dose to maximum efficacy while enabling safer, outpatient-friendly dosing. In non-human primates, CD19-ARM achieved deep and durable B-cell depletion in both blood and lymphoid tissues with a >100x CRS safety window. The CD19-ARM is on track for first-in-human studies to begin in the first half of 2026. Event Information To join the webcast, please visit this link, or the Events & Presentations page of the Investors section on the Company's website A replay of the webcast will be archived and available following the event. Participant Dial-In Numbers: USA / International Toll +1 (646) 307-1963 USA - Toll-Free (800) 715-9871 Conference ID 9235403 Janux's TRACTr, TRACIr and ARM Pipeline Janux's first clinical candidate, JANX007, is a TRACTr that targets prostate-specific membrane antigen (PSMA) and is being investigated in a Phase 1 clinical trial in adult patients with mCRPC. Janux's second clinical candidate, JANX008, is a TRACTr that targets epidermal growth factor receptor (EGFR) and is being studied in a Phase 1 clinical trial for the treatment of multiple solid cancers including colorectal carcinoma, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma and triple-negative breast cancer. Janux is also advancing additional CD3-based TRACTr and CD28-based TRACIr programs for future clinical development, including a PSMA-TRACIr for use in combination with our PSMA-TRACTr JANX007, and a TROP2-TRACTr for the treatment of TROP2+ solid tumors. Janux is also advancing its first ARM platform program candidate, a CD19-ARM for the potential treatment of autoimmune diseases toward clinical trials. About Janux Therapeutics Janux is a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. Janux has two TRACTr therapeutic candidates in clinical trials, the first targeting PSMA is in development for prostate cancer, and the second targeting EGFR is being developed for colorectal carcinoma, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma and triple-negative breast cancer. For more information, please visit and follow us on LinkedIn. Forward-Looking Statements This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, Janux's ability to bring new treatments to cancer patients in need, expectations regarding the timing, scope and results of Janux's development activities, including its ongoing and planned clinical trials, and the potential benefits of Janux's product candidates and platform technologies. Factors that may cause actual results to differ materially include the risk that interim results of a clinical trial are not necessarily indicative of final results and one or more of the clinical outcomes may materially change as patient enrollment continues, following more comprehensive reviews of the data and as more patient data becomes available, including the risk that unconfirmed responses may not ultimately result in confirmed responses to treatment after follow-up evaluations, the risk that compounds that appear promising in early research do not demonstrate safety and/or efficacy in later preclinical studies or clinical trials, the risk that Janux may not obtain approval to market its product candidates, uncertainties associated with performing clinical trials, regulatory filings and applications, risks associated with reliance on third parties to successfully conduct clinical trials, the risks associated with reliance on outside financing to meet capital requirements, and other risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. You are urged to consider statements that include the words 'may,' 'will,' 'would,' 'could,' 'should,' 'believes,' 'estimates,' 'projects,' 'promise,' 'potential,' 'expects,' 'plans,' 'anticipates,' 'intends,' 'continues,' 'designed,' 'goal,' or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties Janux faces, please refer to Janux's periodic and other filings with the Securities and Exchange Commission, which are available at Such forward-looking statements are current only as of the date they are made, and Janux assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
